Ranibizumab

Educational summary, not a formulary. Dosing is quoted from the Makindo chapters and topics site. The other sections are draft summaries not yet checked line by line against the BNF or SPC. Check dose, indication, interactions and monitoring in the BNF entry for Ranibizumab and local guidelines before prescribing.

Anti-VEGF agent

Mechanism

Anti-VEGF antibody fragment.

Uses

Neovascular AMD, diabetic macular oedema.

Dosing

No dose is given in the chapters. See the BNF.

Side effects

Eye pain, raised intraocular pressure, floaters.

Interactions

None significant.

Contraindications and cautions

Active ocular infection

Monitoring

Visual acuity

Pregnancy and breastfeeding

Avoid

Renal and hepatic impairment

No adjustment

Overdose and reversal

Supportive

Special advice

Intravitreal; ophthalmology follow-up.

More from the textbook: uses, cautions and other points
Where it is discussed in the book